Use of hymenialdisine or derivatives thereof in the manufacture of medicaments

Utilisation d'hymenialdisine ou de ses derives pour la fabrication de medicaments

Abstract

The invention relates to the use of hymenialdisine or derivatives thereof of formula (I) in which R1 and R2, identical or different, represent H or Br, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in inhibiting acceptable salt thereof, in the manufacture of a medicament for use in inhibiting cycline dependent kineases, GSK-3β and casein kinase 1. Application for preventing and treating neurodegenerative disorders, including Alzheimers disease, diabetes, inflammatory pathologies and cancers.
L'invention concerne l'utilisation d'hymenialdisine ou de ses dérivés représentés par la formule (I) dans laquelle R1 et R2, identiques ou différents, représentent H ou Br, ou un de leurs sels pharmaceutiquement acceptables, pour la fabrication d'un médicament servant à inhiber les kinases cycline-dépendantes GSK-3β et la caséine kinase 1. L'invention trouve des applications dans le traitement et la prévention des troubles neuro-dégénératifs, du diabète, de pathologies inflammatoires et du cancer.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (4)

    Publication numberPublication dateAssigneeTitle
    US-5621099-AApril 15, 1997Suntory LimitedSynthetic method of hymenialdisine and its derivatives and their synthetic intermediates, and those synthetic intermediates
    WO-9316703-A1September 02, 1993Smithkline Beecham CorporationProtein kinase c inhibitor
    WO-9640147-A1December 19, 1996Osteoarthritis Sciences, Inc., The Reagents Of The University Of CaliforniaUtilisation de la debromohymenialdisine et de composes apparentes pour traiter l'arthrose
    WO-9915157-A2April 01, 1999The University Of British ColumbiaInhibiteurs des points de controle g2 et dosage

NO-Patent Citations (9)

    Title
    BOYD, MICHAEL R. ET AL: "Antineoplastic agents. 362. isolation and X-ray crystal structure of dibromophakellstatin from the Indian Ocean sponge Phakellia mauritiana" J. NAT. PROD. (1997), 60(2), 180-183, XP000893167
    BRETON J J ET AL: "THE NATURAL PRODUCT HYMENIALDISINE INHIBITS INTERLEUKIN-8 PRODUCTION IN U937 CELLS BY INHIBITION OF NUCLEAR FACTOR-KAPPA B" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS,US,AMERICAN SOCIETY FOR PHARMACOLOGY AND, vol. 282, no. 1, 1997, pages 459-466, XP002910635 ISSN: 0022-3565
    DIMARTINO M ET AL: "EFFECTS OF A PROTEIN KINASE C INHIBITOR (PKCI) ON THE DEVELOPMENT OF ADJUVANT-INDUCED ARTHRITIS (AA) IN RATS" INFLAMMATION RESEARCH,CH,BIRKHAEUSER VERLAG, BASEL, vol. 44, no. SUPPL. 02, 1 August 1995 (1995-08-01), pages S123-S124, XP000579391 ISSN: 1023-3830
    IMBURGIA, C. ET AL: "Development and characterization of a high throughput screen for human checkpoint kinase, CHK1." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1999) VOL. 40, PP. 406. MEETING INFO.: 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PHILADELPHIA, PENNSYLVANIA, USA APRIL 10-14, 1999 AMERICAN, XP000891503
    KOBAYASHI, J. ET AL: ".alpha.-Adrenoceptor blocking action of hymenin, a novel marine alkaloid" EXPERIENTIA (1988), 44(1), 86-7, XP000891505
    MEIJER, L. (1) ET AL: "Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent." CHEMISTRY & BIOLOGY (LONDON), (JAN., 2000) VOL. 7, NO. 1, PP. 51-63., XP000901413
    PETTIT, GEORGE R. ET AL: "Antineoplastic agents. 168. Isolation and structure of axinohydantoin" CAN. J. CHEM. (1990), 68(9), 1621-4, XP000891506
    ROSHAK A ET AL: "Inhibition of NFkappaB-mediated interleukin-1beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine." JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1997 NOV) 283 (2) 955-61., XP000893093
    SUPRIYONO, A. ET AL: "Bioactive alkaloids from the tropical marine sponge Axinella carteri" Z. NATURFORSCH., C: BIOSCI. (1995), 50(9/10), 669-74, XP000893152

Cited By (29)

    Publication numberPublication dateAssigneeTitle
    EP-1430120-A1June 23, 2004Alcon, Inc.Inhibitoren der glycogensynthase-kinase-3 (gsk-3) zur glaukombehandlung
    EP-1430120-A4June 20, 2007Alcon IncInhibitoren der glycogensynthase-kinase-3 (gsk-3) zur glaukombehandlung
    EP-2077838-A2July 15, 2009The Rockefeller UniversityVerfahren zur behandlung von verwandten erkrankungen und zusammensetzungen dafür
    EP-2077838-A4October 27, 2010Univ RockefellerVerfahren zur behandlung von verwandten erkrankungen und zusammensetzungen dafür
    EP-2258357-A2December 08, 2010Braincells, Inc.Neurogenesis with acetylcholinesterase inhibitor
    EP-2258358-A2December 08, 2010Braincells, Inc.Neurogenèse avec un inhibiteur de l'acetylcholinestérase
    EP-2258359-A2December 08, 2010Braincells, Inc.Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
    EP-2275095-A2January 19, 2011Braincells, Inc.Neurogenese durch modulation des Muscarinrezeptors
    EP-2275096-A2January 19, 2011Braincells, Inc.Neurogenese par modulation des recepteurs muscariniques
    EP-2281560-A1February 09, 2011Alcon, Inc.Inhibiteurs de la glycogène synthase kinase-3 (GSK-3) pour traiter la neuropathie optique du glaucome
    EP-2314289-A1April 27, 2011Braincells, Inc.Modulation de la neurogenese dont la médiation est assurée par récepteur gaba
    EP-2377530-A2October 19, 2011Braincells, Inc.Modulation of neurogenesis by PDE inhibition
    EP-2377531-A2October 19, 2011Braincells, Inc.Neurogénèse par modulation de l'angiotensine
    EP-2382975-A2November 02, 2011Braincells, Inc.Neurogenese mittels Angiotensin-Modulation
    US-7193079-B1March 20, 2007Board Of Trustees Of Michigan State UniversityPreparation of hymenialdisine derivatives and use thereof
    US-7335769-B2February 26, 2008Board Of Trustees Of Michigan State UniversityPreparation of hymenialdsine derivatives and use thereof
    US-7385055-B2June 10, 2008Board Of Trustees Of Michigan State UniversityPreparation of hymenialdisine derivatives and use thereof
    US-7598288-B2October 06, 2009Alcon, Inc.Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
    US-7601710-B2October 13, 2009Board Of Trustees Of Michigan State UniversityPreparation of hymenialdisine derivatives and use thereof
    US-7732436-B2June 08, 2010Board Of Trustees Of Michigan State UniversityPreparation of hymenialdisine derivatives and use thereof
    US-9532980-B2January 03, 2017The Rockefeller UniversityMethods for the treatment of A-β related disorders and compositions therefor
    WO-0152892-A2July 26, 2001Genzyme CorporationInhibiteurs du trajet de jak/stat et leurs utilisations
    WO-0152892-A3January 24, 2002Genzyme CorpInhibiteurs du trajet de jak/stat et leurs utilisations
    WO-03027275-A1April 03, 2003Alcon, Inc.Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
    WO-2008066626-A2June 05, 2008The Rockefeller UniversityMETHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
    WO-2010099217-A1September 02, 2010Braincells, Inc.Modulation of neurogenesis using d-cycloserine combinations
    WO-2011063115-A1May 26, 2011Braincells Inc.Combinaison d'un agent nootropique avec un ou plusieurs agents neurogènes ou à effet neurogène par synergie pour stimuler ou intensifier la neurogenèse
    WO-2011091033-A1July 28, 2011Braincells, Inc.Modulation de la neurogenèse par des agents ppar
    WO-2016067090-A1May 06, 2016King Abdullah University Of Science And TechnologyAlkaloids from sponge, scaffolds for the inhibition of human immunodeficiency virus (hiv)